Esperion Therapeutics (ESPR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Wall Street expects a year-over-year increase in earnings on lower revenues when Praxis Precision Medicines, Inc. (PRAX) reports results for the quarter ended December 2024. While this widely-known ...